Results for PSMA PET/CT
| Vaccinated (28 patients) | DS (4 patients) | ||||||
|---|---|---|---|---|---|---|---|
| Parameter | Total (31 patients) | Control group (3 patients) | Once (3 patients) | Twice (25 patients) | Once (0 patients) | Twice (4 patients) | Index (%) |
| Mean interval from vaccination to PET/CT (d) | NA | NA | 10 (range, 6–18 d) | 14 (range, 0–24 d) | NA | 12 (range, 1–19 d) | NA |
| Lymphadenopathy | |||||||
| Patients (n) | 26 (84%) | 3 (10%) | 3 (11%) | 20 (71%) | 0 | 4 (100%) | S*, 61.5; Sp*, 0; PPV*, 80; NPV*, 0 |
| LN appearance | |||||||
| Benign | 24 (92%) | 3 (100%) | 3 (100%) | 18 (90%) | 3 (75%)† | ||
| Malignant | 0 | 0 | 0 | 0 | 0† | ||
| Equivocal | 2 (8%) | 0 | 0 | 2 (10%) | 1 (25%)† | ||
| Size (cm) in short axis | 0.3–1.6 | 0.3–0.6 | 0.4–1.6† | 0.7–1.5† | |||
| SUVmax | 1.1–3.1 | 1.1–2 | 1.3–3.1† | 1.4–3.1† | |||
| Arm (patients [n]) | 4 (13%) | 0 | 4 (14%)† | 4 (100%)† | NA | ||
| 0 (0%) | 4 (100%) | 0 (0%) | 4 (100%) | ||||
| DS (patients [n]) | 4 (13%) | 0 | 4 (14%)† | —† | S, 44.4; Sp, 100; PPV, 100; NPV, 37.5 | ||
| 0 | 4 (100%) | —† | |||||
*For unilateral axillary lymphadenopathy only, with increased uptake (SUVmax > 1.0) and benign appearance.
↵†Applies to both once-vaccinated and twice-vaccinated patients.
S = sensitivity; Sp = specificity; NA = not applicable.